Abstract 197P
Background
Tumor mutation burden, intratumor heterogeneity and the cancer related immune infiltrate are associated with response to target and immune therapies in several cancer types. The aim of this study is to establish a computational pathology (CPath) pipeline for investigating useful histopathological features in hematoxylin and eosin (H&E) whole slide images (WSIs). The pipeline allows for the segmentation and classification of nuclei. As an application, a machine learning approach is used to quantify intratumor heterogeneity (ITH) and tumor-infiltrating lymphocyte (TIL) scores.
Methods
We randomly selected 178 invasive ductal carcinomas WSIs from the TCGA database to process. Image annotation and nuclei detection were performed on QuPath by a pathologist using StarDist and used to train a SVM-based nuclei type classifier. The classifier was trained to distinguish between tumor, lymphocyte, and stroma. A total of 113.211 nuclei images were extracted using OpenSlide and used to train an autoencoder for dimensionality reduction. The variability of the WSIs was computed by applying a statistical measure of dispersion to the feature vectors. The TIL score was computed as the average minimum distance between a tumor cell and its nearest lymphocyte neighbor. We used the mutation burden, the ITH, PAM50 classification, nuclear and histological grades data from [https://doi.org/10.1038/nm.3984] to validate our ITH score. The percentage of infiltrating lymphocytes inferred by the quanTIseq pipeline based on RNAseq data was used to validate the SVM model.
Results
The nuclei classifier achieved 88% accuracy on the test set and the 96%/92% sensitivity to tumor/lymphocyte on a validation dataset. The mean squared error of the autoencoder was 0.0004 in the test set. The ITH score was associated with the clonal number of a tumor (x2 = 8.8, p= 0.03). Finally, we observed a positive correlation between the TIL/tumor ratio inferred by the CPath pipeline and the total number of T lymphocytes inferred by quanTIseq (Spearman= 0. 34, p < 0.0001).
Conclusions
We explored a CPath pipeline for detecting and classifying nuclei. The pipeline was used to compute ITH and TIL scores which correlated with validation data. Thus, validating our pipeline.
Legal entity responsible for the study
D.G. Tiezzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Final Analysis of the French Real-World Study EVIDENS: Effectiveness, Safety & Quality of Life At 36 Months of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display
79P - A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC
Presenter: Daqiang Sun
Session: Poster Display
80P - Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01)
Presenter: jun Tang
Session: Poster Display
81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)
Presenter: Marisa Bittoni
Session: Poster Display
82P - The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy: A Focus on First Dose Timing
Presenter: Martin Igor Gomez-Randulfe Rodriguez
Session: Poster Display
84P - Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase 3 CAPSTONE-1 study
Presenter: Ying Cheng
Session: Poster Display
85P - Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Yun Fan
Session: Poster Display
86P - Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): updated efficacy and safety analysis
Presenter: Yan Huang
Session: Poster Display
88P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: MARA PERSANO
Session: Poster Display